PROIMI   05436
PLANTA PILOTO DE PROCESOS INDUSTRIALES MICROBIOLOGICOS
Unidad Ejecutora - UE
congresos y reuniones científicas
Título:
Successful fibrinolytic enzymes production by solid state fermentation with a selected Bionectria sp. wild type strain
Autor/es:
ROVATI, JI; CABRAL, ME; CASTELLANOS, LIC; FARIÑA, JI
Lugar:
Potrero de los Funes San Luis
Reunión:
Congreso; XLVII Reunión Anual de la Sociedad Argentina de Investigación en Bioquímica y Biología Molecular; 2011
Institución organizadora:
Sociedad Argentina de Investigación en Bioquímica y Biología Molecular
Resumen:
Fibrin accumulation in blood vessels increases thrombosis risks promoting myocardial infarction and cardiovascular diseases. Bionectria sp. LY 4.1, a wild fungi isolated from Las Yungas Pedemontana rainforest, was recently reported by our group as a novel and promising fibrinolytic enzyme source. In the present study we attempted the production of fibrinolytic enzymes by solid state fermentation (SSF) with Bionectria sp. LY 4.1 particularly looking for low-cost substrates and simplified operational conditions. The different solid substrates evaluated (polyurethane foam - PUF, bagasse, textured soy flour, soy flour pellets and wheat bran), in adequate amounts, were placed in 500 mL-Erlenmeyer flasks and after sterilization, were inoculated with 10 mL of fresh production medium containing 1 mL of a 72 h-old Bionectria sp. culture. The effect of different conditions of moisture (9, 11, 13, 15, 17%), bed height (1, 2, 4, 6, 8 cm) and particle size (0·25; 0·5; 1 and 2 cm2) was studied. Fibrinolytic activity was determined by the fibrin plate technique and protein concentration by the BCA method. The obtained results confirmed the possibility to produce fibrinolytic enzymes by SSF with Bionectria sp. LY 4.1. Furthermore, assays demonstrated the convenience of using PUF as SS under specific operating conditions over the other substrates tested. The findings herein presented open new frontiers for fungal secondary metabolites production by SSF, allowing to offer an interesting alternative for the production of a high added-value pharmacological product.